Substance abuse in adolescents and young adults: a manual for pediatric and primary care clinicans
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin
De Gruyter
2013
|
| Schriftenreihe: | Health, medicine, and human development
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 |
| Beschreibung: | Print version record |
| Beschreibung: | 1 online resource (xxviii, 401 pages) illustrations |
| ISBN: | 9783110311389 3110311380 9783110311396 3110311399 1306091888 9781306091886 9783110313017 3110313014 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043785331 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160920s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 9783110311389 |9 978-3-11-031138-9 | ||
| 020 | |a 3110311380 |9 3-11-031138-0 | ||
| 020 | |a 9783110311396 |9 978-3-11-031139-6 | ||
| 020 | |a 3110311399 |9 3-11-031139-9 | ||
| 020 | |a 1306091888 |9 1-306-09188-8 | ||
| 020 | |a 9781306091886 |9 978-1-306-09188-6 | ||
| 020 | |a 9783110313017 |9 978-3-11-031301-7 | ||
| 020 | |a 3110313014 |9 3-11-031301-4 | ||
| 035 | |a (ZDB-4-EBA)ocn862809666 | ||
| 035 | |a (OCoLC)862809666 | ||
| 035 | |a (DE-599)BVBBV043785331 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 616.8600835 |2 23 | |
| 245 | 1 | 0 | |a Substance abuse in adolescents and young adults |b a manual for pediatric and primary care clinicans |c edited by Donald E. Greydanus [and three others] |
| 264 | 1 | |a Berlin |b De Gruyter |c 2013 | |
| 300 | |a 1 online resource (xxviii, 401 pages) |b illustrations | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Health, medicine, and human development | |
| 500 | |a Print version record | ||
| 505 | 8 | |a Substance abuse comprises a global biopsychosocial phenomenon for the world as billions of human beings are experimenting with various illicit chemicals and millions are addicted to various substances. By virtue of their complex nature these disorders can be very difficult to treat and not only complicates the natural course of disease but can also adversely impact long term outcomes. This book is aiming to examine this complex situation in adolescents and young adults and also to provide management plans for clinicians to follow. The information will be presented in an easy to follow format to | |
| 505 | 8 | |a Author Index; Foreword; Abbreviations; 1 Introduction: Substance abuse in adolescents and young adults; Section I: Etiology and diagnosis; 2 Neurobiology of substance use disorders; 2.1 Introduction; 2.2 General concepts; 2.2.1 Dopamine; 2.2.2 Serotonin and norepinephrine; 2.2.3 GABA; 2.3 Neuropharmacology of specific drugs; 2.3.1 Stimulants; 2.3.2 Alcohol; 2.3.3 Opioids; 2.3.4 Nicotine/tobacco; 2.3.5 Cannabinoids; 2.4 Summary; 3 Genetic influences on substance abuse disorders; 3.1 Introduction; 3.2 Limitations; 3.3 Gene classes; 3.4 Specific addictions; 3.4.1 Alcohol; 3.4.2 Cannabis | |
| 505 | 8 | |a 3.4.3 Tobacco3.4.4 Others; 3.5 Epigenetic effects; 3.6 Complex diseases; 3.7 Conclusion; 4 Essential diagnostic considerations; 4.1 Introduction; 4.2 Review of the literature; 4.3 Epidemiology; 4.4 Empirical studies of assessment instruments; 4.5 Comorbidity; 4.6 Assessment; 4.7 Screening; 4.8 Diagnosis; 4.9 Biochemical testing; 4.10 Discussion; Section II: Treatment; 5 Psychosocial treatments for substance use disorders; 5.1 Introduction; 5.2 Motivational treatments; 5.2.1 Precontemplation stage; 5.2.2 Contemplation stage; 5.2.3 Preparation stage; 5.2.4 Action stage; 5.2.5 Maintenance stage | |
| 505 | 8 | |a 5.2.6 Contemplation of relapse5.3 CM and community reinforcement approaches (CRAs); 5.3.1 CM; 5.3.2 CRA; 5.4 Cognitive behavioral approaches; 5.4.1 Functional analysis; 5.4.2 Drug refusal skills; 5.4.3 RP; 5.5 Family interventions; 5.5.1 Multidimensional family therapy (MDFT); 5.6 Conclusion; 6 General pharmacotherapy principles; 6.1 Introduction; 6.2 Evaluation for pharmacotherapy; 6.3 When is pharmacotherapy appropriate?; 6.4 Conclusion; 7 Use of pharmacological agents for smoking cessation; 7.1 Introduction; 7.2 Epidemiology; 7.3 Chemistry and pharmacology; 7.4 Effects on health | |
| 505 | 8 | |a 7.5 Behavioral approaches to smoking cessation7.6 Pharmacological agents; 7.6.1 Varenicline; 7.6.2 Bupropion SR; 7.6.3 Nicotine replacement therapies; 7.6.4 Second-line medications; 7.6.5 Vaccine; 7.6.6 E-cigarettes; 7.7 Conclusion; 8 Marijuana: Current concepts and conundrums; 8.1 Introduction; 8.1.1 Cannabis sativa plant; 8.1.2 Prevalence; 8.1.3 Cannabis lab testing; 8.2 Medical adverse effects; 8.2.1 Cannabis hyperemesis; 8.2.2 Dental effects of cannabis; 8.2.3 Pulmonary effects; 8.2.4 Cannabis and cancer; 8.2.5 Cardiovascular effects; 8.2.6 Motor vehicle accidents; 8.2.7 Sports doping | |
| 505 | 8 | |a 8.2.8 Adverse effects: Psychiatric8.2.9 Management; 8.2.10 Pharmacological therapies; 8.2.11 Cannabis intoxication; 8.2.12 Cannabis withdrawal; 8.3 Cannabis-associated psychosis; 8.3.1 Cannabis dependence; 8.4 Summary; 9 Primary care management of alcohol use disorders of adolescents and young adults; 9.1 Introduction; 9.2 Epidemiology: Drinking patterns and beverage preferences; 9.2.1 Drinking patterns; 9.2.2 Drinking preferences; 9.3 Confidentiality in primary care; 9.4 Screening in primary care; 9.4.1 Screening; 9.4.2 Screening tools; 9.5 Assessment of risk | |
| 505 | 8 | |a 9.5.1 Screening the college student | |
| 650 | 7 | |a HEALTH & FITNESS / Diseases / General |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Clinical Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Diseases |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Evidence-Based Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Internal Medicine |2 bisacsh | |
| 650 | 7 | |a Substance abuse / Treatment |2 fast | |
| 650 | 7 | |a Teenagers / Substance use |2 fast | |
| 650 | 7 | |a Young adults / Substance use |2 fast | |
| 650 | 4 | |a Substance abuse / Treatment / United States | |
| 650 | 4 | |a Substance abuse / Treatment | |
| 650 | 4 | |a Evidenz-basierte Medizin | |
| 650 | 4 | |a Innere Medizin | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Substance abuse |x Treatment |a Teenagers |x Substance use |a Young adults |x Substance use | |
| 651 | 4 | |a USA | |
| 700 | 1 | |a Greydanus, Donald E. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Substance abuse in adolescents and young adults |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029196391 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=661737 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=661737 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176619388010496 |
|---|---|
| any_adam_object | |
| author2 | Greydanus, Donald E. |
| author2_role | edt |
| author2_variant | d e g de deg |
| author_facet | Greydanus, Donald E. |
| building | Verbundindex |
| bvnumber | BV043785331 |
| collection | ZDB-4-EBA |
| contents | Substance abuse comprises a global biopsychosocial phenomenon for the world as billions of human beings are experimenting with various illicit chemicals and millions are addicted to various substances. By virtue of their complex nature these disorders can be very difficult to treat and not only complicates the natural course of disease but can also adversely impact long term outcomes. This book is aiming to examine this complex situation in adolescents and young adults and also to provide management plans for clinicians to follow. The information will be presented in an easy to follow format to Author Index; Foreword; Abbreviations; 1 Introduction: Substance abuse in adolescents and young adults; Section I: Etiology and diagnosis; 2 Neurobiology of substance use disorders; 2.1 Introduction; 2.2 General concepts; 2.2.1 Dopamine; 2.2.2 Serotonin and norepinephrine; 2.2.3 GABA; 2.3 Neuropharmacology of specific drugs; 2.3.1 Stimulants; 2.3.2 Alcohol; 2.3.3 Opioids; 2.3.4 Nicotine/tobacco; 2.3.5 Cannabinoids; 2.4 Summary; 3 Genetic influences on substance abuse disorders; 3.1 Introduction; 3.2 Limitations; 3.3 Gene classes; 3.4 Specific addictions; 3.4.1 Alcohol; 3.4.2 Cannabis 3.4.3 Tobacco3.4.4 Others; 3.5 Epigenetic effects; 3.6 Complex diseases; 3.7 Conclusion; 4 Essential diagnostic considerations; 4.1 Introduction; 4.2 Review of the literature; 4.3 Epidemiology; 4.4 Empirical studies of assessment instruments; 4.5 Comorbidity; 4.6 Assessment; 4.7 Screening; 4.8 Diagnosis; 4.9 Biochemical testing; 4.10 Discussion; Section II: Treatment; 5 Psychosocial treatments for substance use disorders; 5.1 Introduction; 5.2 Motivational treatments; 5.2.1 Precontemplation stage; 5.2.2 Contemplation stage; 5.2.3 Preparation stage; 5.2.4 Action stage; 5.2.5 Maintenance stage 5.2.6 Contemplation of relapse5.3 CM and community reinforcement approaches (CRAs); 5.3.1 CM; 5.3.2 CRA; 5.4 Cognitive behavioral approaches; 5.4.1 Functional analysis; 5.4.2 Drug refusal skills; 5.4.3 RP; 5.5 Family interventions; 5.5.1 Multidimensional family therapy (MDFT); 5.6 Conclusion; 6 General pharmacotherapy principles; 6.1 Introduction; 6.2 Evaluation for pharmacotherapy; 6.3 When is pharmacotherapy appropriate?; 6.4 Conclusion; 7 Use of pharmacological agents for smoking cessation; 7.1 Introduction; 7.2 Epidemiology; 7.3 Chemistry and pharmacology; 7.4 Effects on health 7.5 Behavioral approaches to smoking cessation7.6 Pharmacological agents; 7.6.1 Varenicline; 7.6.2 Bupropion SR; 7.6.3 Nicotine replacement therapies; 7.6.4 Second-line medications; 7.6.5 Vaccine; 7.6.6 E-cigarettes; 7.7 Conclusion; 8 Marijuana: Current concepts and conundrums; 8.1 Introduction; 8.1.1 Cannabis sativa plant; 8.1.2 Prevalence; 8.1.3 Cannabis lab testing; 8.2 Medical adverse effects; 8.2.1 Cannabis hyperemesis; 8.2.2 Dental effects of cannabis; 8.2.3 Pulmonary effects; 8.2.4 Cannabis and cancer; 8.2.5 Cardiovascular effects; 8.2.6 Motor vehicle accidents; 8.2.7 Sports doping 8.2.8 Adverse effects: Psychiatric8.2.9 Management; 8.2.10 Pharmacological therapies; 8.2.11 Cannabis intoxication; 8.2.12 Cannabis withdrawal; 8.3 Cannabis-associated psychosis; 8.3.1 Cannabis dependence; 8.4 Summary; 9 Primary care management of alcohol use disorders of adolescents and young adults; 9.1 Introduction; 9.2 Epidemiology: Drinking patterns and beverage preferences; 9.2.1 Drinking patterns; 9.2.2 Drinking preferences; 9.3 Confidentiality in primary care; 9.4 Screening in primary care; 9.4.1 Screening; 9.4.2 Screening tools; 9.5 Assessment of risk 9.5.1 Screening the college student |
| ctrlnum | (ZDB-4-EBA)ocn862809666 (OCoLC)862809666 (DE-599)BVBBV043785331 |
| dewey-full | 616.8600835 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.8600835 |
| dewey-search | 616.8600835 |
| dewey-sort | 3616.8600835 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06182nmm a2200697zc 4500</leader><controlfield tag="001">BV043785331</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160920s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783110311389</subfield><subfield code="9">978-3-11-031138-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3110311380</subfield><subfield code="9">3-11-031138-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783110311396</subfield><subfield code="9">978-3-11-031139-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3110311399</subfield><subfield code="9">3-11-031139-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1306091888</subfield><subfield code="9">1-306-09188-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781306091886</subfield><subfield code="9">978-1-306-09188-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783110313017</subfield><subfield code="9">978-3-11-031301-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3110313014</subfield><subfield code="9">3-11-031301-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-EBA)ocn862809666</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)862809666</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043785331</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.8600835</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Substance abuse in adolescents and young adults</subfield><subfield code="b">a manual for pediatric and primary care clinicans</subfield><subfield code="c">edited by Donald E. Greydanus [and three others]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin</subfield><subfield code="b">De Gruyter</subfield><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xxviii, 401 pages)</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Health, medicine, and human development</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Print version record</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Substance abuse comprises a global biopsychosocial phenomenon for the world as billions of human beings are experimenting with various illicit chemicals and millions are addicted to various substances. By virtue of their complex nature these disorders can be very difficult to treat and not only complicates the natural course of disease but can also adversely impact long term outcomes. This book is aiming to examine this complex situation in adolescents and young adults and also to provide management plans for clinicians to follow. The information will be presented in an easy to follow format to</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Author Index; Foreword; Abbreviations; 1 Introduction: Substance abuse in adolescents and young adults; Section I: Etiology and diagnosis; 2 Neurobiology of substance use disorders; 2.1 Introduction; 2.2 General concepts; 2.2.1 Dopamine; 2.2.2 Serotonin and norepinephrine; 2.2.3 GABA; 2.3 Neuropharmacology of specific drugs; 2.3.1 Stimulants; 2.3.2 Alcohol; 2.3.3 Opioids; 2.3.4 Nicotine/tobacco; 2.3.5 Cannabinoids; 2.4 Summary; 3 Genetic influences on substance abuse disorders; 3.1 Introduction; 3.2 Limitations; 3.3 Gene classes; 3.4 Specific addictions; 3.4.1 Alcohol; 3.4.2 Cannabis</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3.4.3 Tobacco3.4.4 Others; 3.5 Epigenetic effects; 3.6 Complex diseases; 3.7 Conclusion; 4 Essential diagnostic considerations; 4.1 Introduction; 4.2 Review of the literature; 4.3 Epidemiology; 4.4 Empirical studies of assessment instruments; 4.5 Comorbidity; 4.6 Assessment; 4.7 Screening; 4.8 Diagnosis; 4.9 Biochemical testing; 4.10 Discussion; Section II: Treatment; 5 Psychosocial treatments for substance use disorders; 5.1 Introduction; 5.2 Motivational treatments; 5.2.1 Precontemplation stage; 5.2.2 Contemplation stage; 5.2.3 Preparation stage; 5.2.4 Action stage; 5.2.5 Maintenance stage</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5.2.6 Contemplation of relapse5.3 CM and community reinforcement approaches (CRAs); 5.3.1 CM; 5.3.2 CRA; 5.4 Cognitive behavioral approaches; 5.4.1 Functional analysis; 5.4.2 Drug refusal skills; 5.4.3 RP; 5.5 Family interventions; 5.5.1 Multidimensional family therapy (MDFT); 5.6 Conclusion; 6 General pharmacotherapy principles; 6.1 Introduction; 6.2 Evaluation for pharmacotherapy; 6.3 When is pharmacotherapy appropriate?; 6.4 Conclusion; 7 Use of pharmacological agents for smoking cessation; 7.1 Introduction; 7.2 Epidemiology; 7.3 Chemistry and pharmacology; 7.4 Effects on health</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">7.5 Behavioral approaches to smoking cessation7.6 Pharmacological agents; 7.6.1 Varenicline; 7.6.2 Bupropion SR; 7.6.3 Nicotine replacement therapies; 7.6.4 Second-line medications; 7.6.5 Vaccine; 7.6.6 E-cigarettes; 7.7 Conclusion; 8 Marijuana: Current concepts and conundrums; 8.1 Introduction; 8.1.1 Cannabis sativa plant; 8.1.2 Prevalence; 8.1.3 Cannabis lab testing; 8.2 Medical adverse effects; 8.2.1 Cannabis hyperemesis; 8.2.2 Dental effects of cannabis; 8.2.3 Pulmonary effects; 8.2.4 Cannabis and cancer; 8.2.5 Cardiovascular effects; 8.2.6 Motor vehicle accidents; 8.2.7 Sports doping</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">8.2.8 Adverse effects: Psychiatric8.2.9 Management; 8.2.10 Pharmacological therapies; 8.2.11 Cannabis intoxication; 8.2.12 Cannabis withdrawal; 8.3 Cannabis-associated psychosis; 8.3.1 Cannabis dependence; 8.4 Summary; 9 Primary care management of alcohol use disorders of adolescents and young adults; 9.1 Introduction; 9.2 Epidemiology: Drinking patterns and beverage preferences; 9.2.1 Drinking patterns; 9.2.2 Drinking preferences; 9.3 Confidentiality in primary care; 9.4 Screening in primary care; 9.4.1 Screening; 9.4.2 Screening tools; 9.5 Assessment of risk</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">9.5.1 Screening the college student</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Diseases / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Clinical Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Diseases</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Evidence-Based Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Internal Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Substance abuse / Treatment</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Teenagers / Substance use</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Young adults / Substance use</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Substance abuse / Treatment / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Substance abuse / Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Evidenz-basierte Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Innere Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Substance abuse</subfield><subfield code="x">Treatment</subfield><subfield code="a">Teenagers</subfield><subfield code="x">Substance use</subfield><subfield code="a">Young adults</subfield><subfield code="x">Substance use</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Greydanus, Donald E.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Substance abuse in adolescents and young adults</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029196391</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=661737</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=661737</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043785331 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:35:04Z |
| institution | BVB |
| isbn | 9783110311389 3110311380 9783110311396 3110311399 1306091888 9781306091886 9783110313017 3110313014 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029196391 |
| oclc_num | 862809666 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 online resource (xxviii, 401 pages) illustrations |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | De Gruyter |
| record_format | marc |
| series2 | Health, medicine, and human development |
| spelling | Substance abuse in adolescents and young adults a manual for pediatric and primary care clinicans edited by Donald E. Greydanus [and three others] Berlin De Gruyter 2013 1 online resource (xxviii, 401 pages) illustrations txt rdacontent c rdamedia cr rdacarrier Health, medicine, and human development Print version record Substance abuse comprises a global biopsychosocial phenomenon for the world as billions of human beings are experimenting with various illicit chemicals and millions are addicted to various substances. By virtue of their complex nature these disorders can be very difficult to treat and not only complicates the natural course of disease but can also adversely impact long term outcomes. This book is aiming to examine this complex situation in adolescents and young adults and also to provide management plans for clinicians to follow. The information will be presented in an easy to follow format to Author Index; Foreword; Abbreviations; 1 Introduction: Substance abuse in adolescents and young adults; Section I: Etiology and diagnosis; 2 Neurobiology of substance use disorders; 2.1 Introduction; 2.2 General concepts; 2.2.1 Dopamine; 2.2.2 Serotonin and norepinephrine; 2.2.3 GABA; 2.3 Neuropharmacology of specific drugs; 2.3.1 Stimulants; 2.3.2 Alcohol; 2.3.3 Opioids; 2.3.4 Nicotine/tobacco; 2.3.5 Cannabinoids; 2.4 Summary; 3 Genetic influences on substance abuse disorders; 3.1 Introduction; 3.2 Limitations; 3.3 Gene classes; 3.4 Specific addictions; 3.4.1 Alcohol; 3.4.2 Cannabis 3.4.3 Tobacco3.4.4 Others; 3.5 Epigenetic effects; 3.6 Complex diseases; 3.7 Conclusion; 4 Essential diagnostic considerations; 4.1 Introduction; 4.2 Review of the literature; 4.3 Epidemiology; 4.4 Empirical studies of assessment instruments; 4.5 Comorbidity; 4.6 Assessment; 4.7 Screening; 4.8 Diagnosis; 4.9 Biochemical testing; 4.10 Discussion; Section II: Treatment; 5 Psychosocial treatments for substance use disorders; 5.1 Introduction; 5.2 Motivational treatments; 5.2.1 Precontemplation stage; 5.2.2 Contemplation stage; 5.2.3 Preparation stage; 5.2.4 Action stage; 5.2.5 Maintenance stage 5.2.6 Contemplation of relapse5.3 CM and community reinforcement approaches (CRAs); 5.3.1 CM; 5.3.2 CRA; 5.4 Cognitive behavioral approaches; 5.4.1 Functional analysis; 5.4.2 Drug refusal skills; 5.4.3 RP; 5.5 Family interventions; 5.5.1 Multidimensional family therapy (MDFT); 5.6 Conclusion; 6 General pharmacotherapy principles; 6.1 Introduction; 6.2 Evaluation for pharmacotherapy; 6.3 When is pharmacotherapy appropriate?; 6.4 Conclusion; 7 Use of pharmacological agents for smoking cessation; 7.1 Introduction; 7.2 Epidemiology; 7.3 Chemistry and pharmacology; 7.4 Effects on health 7.5 Behavioral approaches to smoking cessation7.6 Pharmacological agents; 7.6.1 Varenicline; 7.6.2 Bupropion SR; 7.6.3 Nicotine replacement therapies; 7.6.4 Second-line medications; 7.6.5 Vaccine; 7.6.6 E-cigarettes; 7.7 Conclusion; 8 Marijuana: Current concepts and conundrums; 8.1 Introduction; 8.1.1 Cannabis sativa plant; 8.1.2 Prevalence; 8.1.3 Cannabis lab testing; 8.2 Medical adverse effects; 8.2.1 Cannabis hyperemesis; 8.2.2 Dental effects of cannabis; 8.2.3 Pulmonary effects; 8.2.4 Cannabis and cancer; 8.2.5 Cardiovascular effects; 8.2.6 Motor vehicle accidents; 8.2.7 Sports doping 8.2.8 Adverse effects: Psychiatric8.2.9 Management; 8.2.10 Pharmacological therapies; 8.2.11 Cannabis intoxication; 8.2.12 Cannabis withdrawal; 8.3 Cannabis-associated psychosis; 8.3.1 Cannabis dependence; 8.4 Summary; 9 Primary care management of alcohol use disorders of adolescents and young adults; 9.1 Introduction; 9.2 Epidemiology: Drinking patterns and beverage preferences; 9.2.1 Drinking patterns; 9.2.2 Drinking preferences; 9.3 Confidentiality in primary care; 9.4 Screening in primary care; 9.4.1 Screening; 9.4.2 Screening tools; 9.5 Assessment of risk 9.5.1 Screening the college student HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Substance abuse / Treatment fast Teenagers / Substance use fast Young adults / Substance use fast Substance abuse / Treatment / United States Substance abuse / Treatment Evidenz-basierte Medizin Innere Medizin Medizin Substance abuse Treatment Teenagers Substance use Young adults Substance use USA Greydanus, Donald E. edt Erscheint auch als Druck-Ausgabe Substance abuse in adolescents and young adults |
| spellingShingle | Substance abuse in adolescents and young adults a manual for pediatric and primary care clinicans Substance abuse comprises a global biopsychosocial phenomenon for the world as billions of human beings are experimenting with various illicit chemicals and millions are addicted to various substances. By virtue of their complex nature these disorders can be very difficult to treat and not only complicates the natural course of disease but can also adversely impact long term outcomes. This book is aiming to examine this complex situation in adolescents and young adults and also to provide management plans for clinicians to follow. The information will be presented in an easy to follow format to Author Index; Foreword; Abbreviations; 1 Introduction: Substance abuse in adolescents and young adults; Section I: Etiology and diagnosis; 2 Neurobiology of substance use disorders; 2.1 Introduction; 2.2 General concepts; 2.2.1 Dopamine; 2.2.2 Serotonin and norepinephrine; 2.2.3 GABA; 2.3 Neuropharmacology of specific drugs; 2.3.1 Stimulants; 2.3.2 Alcohol; 2.3.3 Opioids; 2.3.4 Nicotine/tobacco; 2.3.5 Cannabinoids; 2.4 Summary; 3 Genetic influences on substance abuse disorders; 3.1 Introduction; 3.2 Limitations; 3.3 Gene classes; 3.4 Specific addictions; 3.4.1 Alcohol; 3.4.2 Cannabis 3.4.3 Tobacco3.4.4 Others; 3.5 Epigenetic effects; 3.6 Complex diseases; 3.7 Conclusion; 4 Essential diagnostic considerations; 4.1 Introduction; 4.2 Review of the literature; 4.3 Epidemiology; 4.4 Empirical studies of assessment instruments; 4.5 Comorbidity; 4.6 Assessment; 4.7 Screening; 4.8 Diagnosis; 4.9 Biochemical testing; 4.10 Discussion; Section II: Treatment; 5 Psychosocial treatments for substance use disorders; 5.1 Introduction; 5.2 Motivational treatments; 5.2.1 Precontemplation stage; 5.2.2 Contemplation stage; 5.2.3 Preparation stage; 5.2.4 Action stage; 5.2.5 Maintenance stage 5.2.6 Contemplation of relapse5.3 CM and community reinforcement approaches (CRAs); 5.3.1 CM; 5.3.2 CRA; 5.4 Cognitive behavioral approaches; 5.4.1 Functional analysis; 5.4.2 Drug refusal skills; 5.4.3 RP; 5.5 Family interventions; 5.5.1 Multidimensional family therapy (MDFT); 5.6 Conclusion; 6 General pharmacotherapy principles; 6.1 Introduction; 6.2 Evaluation for pharmacotherapy; 6.3 When is pharmacotherapy appropriate?; 6.4 Conclusion; 7 Use of pharmacological agents for smoking cessation; 7.1 Introduction; 7.2 Epidemiology; 7.3 Chemistry and pharmacology; 7.4 Effects on health 7.5 Behavioral approaches to smoking cessation7.6 Pharmacological agents; 7.6.1 Varenicline; 7.6.2 Bupropion SR; 7.6.3 Nicotine replacement therapies; 7.6.4 Second-line medications; 7.6.5 Vaccine; 7.6.6 E-cigarettes; 7.7 Conclusion; 8 Marijuana: Current concepts and conundrums; 8.1 Introduction; 8.1.1 Cannabis sativa plant; 8.1.2 Prevalence; 8.1.3 Cannabis lab testing; 8.2 Medical adverse effects; 8.2.1 Cannabis hyperemesis; 8.2.2 Dental effects of cannabis; 8.2.3 Pulmonary effects; 8.2.4 Cannabis and cancer; 8.2.5 Cardiovascular effects; 8.2.6 Motor vehicle accidents; 8.2.7 Sports doping 8.2.8 Adverse effects: Psychiatric8.2.9 Management; 8.2.10 Pharmacological therapies; 8.2.11 Cannabis intoxication; 8.2.12 Cannabis withdrawal; 8.3 Cannabis-associated psychosis; 8.3.1 Cannabis dependence; 8.4 Summary; 9 Primary care management of alcohol use disorders of adolescents and young adults; 9.1 Introduction; 9.2 Epidemiology: Drinking patterns and beverage preferences; 9.2.1 Drinking patterns; 9.2.2 Drinking preferences; 9.3 Confidentiality in primary care; 9.4 Screening in primary care; 9.4.1 Screening; 9.4.2 Screening tools; 9.5 Assessment of risk 9.5.1 Screening the college student HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Substance abuse / Treatment fast Teenagers / Substance use fast Young adults / Substance use fast Substance abuse / Treatment / United States Substance abuse / Treatment Evidenz-basierte Medizin Innere Medizin Medizin Substance abuse Treatment Teenagers Substance use Young adults Substance use |
| title | Substance abuse in adolescents and young adults a manual for pediatric and primary care clinicans |
| title_auth | Substance abuse in adolescents and young adults a manual for pediatric and primary care clinicans |
| title_exact_search | Substance abuse in adolescents and young adults a manual for pediatric and primary care clinicans |
| title_full | Substance abuse in adolescents and young adults a manual for pediatric and primary care clinicans edited by Donald E. Greydanus [and three others] |
| title_fullStr | Substance abuse in adolescents and young adults a manual for pediatric and primary care clinicans edited by Donald E. Greydanus [and three others] |
| title_full_unstemmed | Substance abuse in adolescents and young adults a manual for pediatric and primary care clinicans edited by Donald E. Greydanus [and three others] |
| title_short | Substance abuse in adolescents and young adults |
| title_sort | substance abuse in adolescents and young adults a manual for pediatric and primary care clinicans |
| title_sub | a manual for pediatric and primary care clinicans |
| topic | HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Substance abuse / Treatment fast Teenagers / Substance use fast Young adults / Substance use fast Substance abuse / Treatment / United States Substance abuse / Treatment Evidenz-basierte Medizin Innere Medizin Medizin Substance abuse Treatment Teenagers Substance use Young adults Substance use |
| topic_facet | HEALTH & FITNESS / Diseases / General MEDICAL / Clinical Medicine MEDICAL / Diseases MEDICAL / Evidence-Based Medicine MEDICAL / Internal Medicine Substance abuse / Treatment Teenagers / Substance use Young adults / Substance use Substance abuse / Treatment / United States Evidenz-basierte Medizin Innere Medizin Medizin Substance abuse Treatment Teenagers Substance use Young adults Substance use USA |
| work_keys_str_mv | AT greydanusdonalde substanceabuseinadolescentsandyoungadultsamanualforpediatricandprimarycareclinicans |